To date, the Canadian government has allocated $1 billion to the five existing agreements. These include some of the advances that pharmaceutical companies need to support vaccine development, testing and manufacturing. Similarly, Don Davies, an NDP health critic, said the development was good news, but that there were no problems with the cost and accessibility of a potential vaccine. Minister Anand announced that the Canadian government has signed an agreement with Gilead Sciences and McKesson Canada to deliver up to 150,000 vials of Remdesivir, with deliveries beginning this month and continuing through early 2021. Currently, Remdesivir is the only known antiviral drug that has been proven to be effective in the treatment of patients with COVID 19. “In the United States… They have ten times the Canadian population,” said Michael Mullette, Managing Director of Moderna`s new Canadian subsidiary. “If the government decides to invest in pandemic vaccine preparation, it is able to do so on a large scale.” Therefore, if Canada and other rich countries continue to unwittingly supplant access to poor countries in their immunization nationalism, they should offset the investments these countries need to support social protection, income assistance and food security, which are fundamental to the health of their citizens, and strengthen their health systems with the capacity of public health to repress homes when they occur. “We need to make significant investments to ensure that Canada is well positioned to ensure access to successful vaccines or vaccines,” Anand said in an interview with The Canadian Press.
Britain defends vaccine regulator COVID after Fauci`s criticisms “This agreement between the Canadian government and Medicago ensures that Canadians have access to another promising candidate for the COVID-19 vaccine. Medicago is working diligently here in Canada to support the response to COVID-19 and protect the health and safety of Canadians,” said Anita Anand, Minister of Public Services and Supply. On March 12, Medicago announced the successful production of Coronavirus Virus-Like Particle (VLP) in just 20 days after receiving the viral gene, with a viable vaccine candidate for COVID-19. Medicago launched preclinical studies with financial support from the Quebec government and began on July 14 with phase 1 tests in human volunteers. Medicago plans to launch Phase 2 studies in early November and Phase 3 studies shortly thereafter, in December 2020. The Canadian government provided US$173 million for vaccine research and development, and the domestic production capacity of Pfizer and BioNtech said their final results, released Wednesday, proved their vaccine candidate 95 percent effective in preventing COVID-19, while Moderna`s preliminary data from an ongoing study that claimed its vaccine candidate was 94.5 percent effective. “We are well ahead of our vaccine suppliers in our negotiations and purchases so far,” Anand said. “Of course, we follow science. As a result, no vaccine would be distributed in Canada without Health Canada`s approval, including the Pfizer vaccine. This figure would be sufficient to vaccinate “five times” the entire population of Canada and outperform any other country in terms of confirmed orders for COVID 19 vaccines per capita, according to an analysis of data compiled by Duke University. “We are confident that our vaccine candidate will be successful and look forward to sharing the results of Phase 1 in the coming weeks,” said Nathalie Landry, Executive Vice President, Scientific Research and Medical Affairs at Medicago.
